Humacyte (NASDAQ:HUMA) Stock Rating Reaffirmed by BTIG Research

BTIG Research reissued their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report released on Friday morning, Marketbeat.com reports. BTIG Research currently has a $10.00 price target on the stock.

Other analysts have also issued reports about the company. Benchmark reiterated a “buy” rating and set a $15.00 price objective on shares of Humacyte in a report on Thursday, October 10th. EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 price target on shares of Humacyte in a report on Friday, September 20th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $10.00.

Humacyte Stock Up 6.2 %

HUMA stock opened at $5.34 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 5.41 and a quick ratio of 5.41. The firm has a market cap of $635.91 million, a PE ratio of -5.34 and a beta of 1.45. Humacyte has a 12 month low of $1.96 and a 12 month high of $9.97. The firm has a 50 day simple moving average of $5.75 and a 200 day simple moving average of $5.95.

Humacyte (NASDAQ:HUMA) last released its earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Equities research analysts forecast that Humacyte will post -1.09 earnings per share for the current fiscal year.

Insider Transactions at Humacyte

In related news, Director Kathleen Sebelius sold 5,182 shares of Humacyte stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total transaction of $27,982.80. Following the transaction, the director now owns 40,276 shares of the company’s stock, valued at $217,490.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Brady W. Dougan sold 352,112 shares of the company’s stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $6.35, for a total transaction of $2,235,911.20. Following the completion of the transaction, the director now directly owns 3,677,262 shares of the company’s stock, valued at $23,350,613.70. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kathleen Sebelius sold 5,182 shares of Humacyte stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total transaction of $27,982.80. Following the completion of the sale, the director now owns 40,276 shares in the company, valued at $217,490.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,084,153 shares of company stock worth $6,869,996 in the last three months. Insiders own 23.10% of the company’s stock.

Institutional Trading of Humacyte

Several institutional investors and hedge funds have recently added to or reduced their stakes in HUMA. nVerses Capital LLC acquired a new position in Humacyte during the second quarter worth approximately $28,000. Hartline Investment Corp acquired a new stake in shares of Humacyte in the first quarter valued at approximately $70,000. Principal Financial Group Inc. bought a new position in shares of Humacyte during the 2nd quarter worth approximately $83,000. Profund Advisors LLC acquired a new position in shares of Humacyte during the 2nd quarter worth approximately $97,000. Finally, XTX Topco Ltd acquired a new position in shares of Humacyte during the 2nd quarter worth approximately $110,000. 44.71% of the stock is owned by institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.